North America Cervical Cancer Diagnostic Market – Industry Trends and Forecast to 2030

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

North America Cervical Cancer Diagnostic Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Publish Reports
  • Dec 2022
  • North America
  • 350 Pages
  • Nombre de tableaux : 79
  • Nombre de figures : 39

North America Cervical Cancer Diagnostic Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2030
Diagram Taille du marché (année de référence)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram Taille du marché (année de prévision)
Dollars américains 5,516.97
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché nord-américain du diagnostic du cancer du col de l'utérus, par type de produit (test d'imagerie, test de dépistage, examen visuel, biopsies cervicales et autres procédures), groupe d'âge (moins de 21 ans, 21-29 ans, 30-65 ans, 65 ans et plus), stades (stade I, stade II, stade III, stade IV), utilisateurs finaux (hôpitaux, laboratoires de diagnostic, cliniques spécialisées, centres de santé communautaires, organisation de recherche sur le cancer, centres de cancérologie et de radiothérapie), canal de distribution (appel d'offres direct, ventes au détail, ventes en ligne) - Tendances et prévisions de l'industrie jusqu'en 2030.

Marché nord-américain du diagnostic du cancer du col de l'utérus

Analyse et perspectives du marché du diagnostic du cancer du col de l'utérus en Amérique du Nord 

Le marché nord-américain du diagnostic du cancer du col de l'utérus connaît une croissance au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs du marché et de la disponibilité de divers produits et marques de diagnostic du cancer du col de l'utérus. Parallèlement à cela, les acteurs du marché sont engagés dans des diagnostics avancés du cancer du col de l'utérus. La prévalence croissante du cancer du col de l'utérus devrait encore stimuler la croissance du marché. Cependant, les règles et réglementations strictes pourraient freiner la croissance du marché au cours de la période de prévision. Les diverses collaborations gouvernementales et privées, l'augmentation des activités de R&D et les initiatives stratégiques des acteurs du marché offrent des opportunités au marché. Cependant, les faux résultats des tests de dépistage du cancer du col de l'utérus devraient constituer un défi majeur pour la croissance du marché.

Marché nord-américain du diagnostic du cancer du col de l'utérus

Marché nord-américain du diagnostic du cancer du col de l'utérus

Le marché du diagnostic du cancer du col de l'utérus en Amérique du Nord devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 7,0 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 5 516,97 millions USD d'ici 2030.

Rapport métrique

Détails

Période de prévision

2023 à 2030

Année de base

2022

Années historiques

2021 (personnalisable pour 2020-2015)

Unités quantitatives

Chiffre d'affaires en millions USD

Segments couverts

Par type de produit (test d'imagerie, test de dépistage, examen visuel, biopsies cervicales et autres procédures), groupe d'âge (moins de 21 ans, 21-29 ans, 30-65 ans, 65 ans et plus), stades (stade I, stade II, stade III, stade IV), utilisateurs finaux (hôpitaux, laboratoires de diagnostic, cliniques spécialisées, centres de santé communautaires, organismes de recherche sur le cancer, centres de cancérologie et de radiothérapie), canal de distribution (appel d'offres direct, ventes au détail, ventes en ligne)

Pays couverts

États-Unis, Canada, Mexique

Acteurs du marché couverts

Siemens Healthcare GmbH, BD, F. Hoffmann-La Roche Ltd, Abbott, Hologic, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., QIAGEN, The Cooper Companies Inc., Seegene Inc., Sysmex Corporation, MobileODT, Zilico, Jiangsu Mole Bioscience Co. Ltd., Guided Therapeutics, Inc., GenomeMe Lab Inc., Arbor Vita Corporation et LCM GENECT Srl, entre autres

Définition du marché :

Cervical cancer is a type of cancer that develops in the cervix of the female reproductive tract. It is becoming more prevalent as the number of HPV-infected patients increases, and there is a greater emphasis on early detection and treatment, which is expected to accelerate the development of cervical cancer diagnosis. Increasing government investment in raising awareness about early cancer detection and increasing healthcare spending would also propel business growth. The most common cause of cervical cancer is HPV (Human Papillomavirus) infection. Other lifestyle choices that can raise the risk include smoking, drinking, a diet low in fruits, and vegetables, taking birth control pills, and teenage sexual encounters. Since, cervical cancer is treatable once diagnosed in an early stage, women at risk of developing the disease must undergo routine testing to identify the disease early, allowing the market to expand.

North America Cervical Cancer Diagnostic Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Rising awareness of the early diagnosis of cervical cancer

There is an enormous range of risk factors being reported for cervical cancer. Therefore awareness about its diagnosis has increased in recent years. Various diagnostic tests are available, such as PAP (Papanicolaou) testing, human papillomavirus testing, colposcopy, cervical biopsies, and cystoscopy among others. Hence, to reduce the risk factors, early diagnosis is very important.

  • Increasing prevalence and incidence of cervical cancer

Cervical cancer is a type of cancer that develops in the female reproductive tract's cervix. The irregular development of cancer cells in the cervix tissue frequently defines cervical cancer. Adenocarcinoma or squamous cell carcinoma can develop from cervical cancer. The most common cause of cervical cancer is HPV (Human Papillomavirus) infection. Cervical cancer is classified into two types' adenocarcinoma and squamous cell carcinoma. Cervical cancer is diagnosed using a variety of advanced laboratory tests, tools, and procedures that evaluate abnormal cells and strains of the human papillomavirus (HPV).

Opportunities

  • Rising healthcare expenditure

Healthcare expenditure has increased worldwide as people's disposable income in various countries increases. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative to accelerate healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities on cervical cancer diagnostic as the disorder has been highly prevalent in recent years.

Also, the strategic initiatives key market players take will provide structural integrity and future opportunities for the North America cervical cancer diagnostic market in the forecast period.

Restraints/Challenges

However, cervical cancer diagnostic drugs may have adverse side effects; it is challenging to balance the risks with the benefits of treatment due to the increasing side effects of cancer medication hampering the market demand.

Moreover, increasing approvals of HPV vaccines by regulatory authorities are expected to hinder the growth of the North America cervical cancer diagnostic market. These developments are rapidly happening across the globe to reduce the cases of cervical cancer, which can be a restraining factor for the market.

The use of various treatment drugs across the globe is rapidly increasing, and with the increasing prevalence of cervical cancer, there is a need for timely diagnosis and treatment. At the same time, the players of the cervical cancer diagnostic manufacturers in the market have to follow certain regulations to get approval from the upper authorities for launching the product in the market. These stringent guidelines need to be followed; this is one of the most difficult tasks of all the steps. The pre-market approval of various medical drugs varies from one country to another.

Recent Development

  • In August 2020, Siemens Healthcare GmbH agreed with Varian Medical Systems, Inc. for acquisition; with this acquisition, Siemens Healthcare has helped develop advanced solutions to treat cancer and strengthen its position in the healthcare industry

North America Cervical Cancer Diagnostic Market Scope

The North America cervical cancer diagnostic market is segmented into product type, age group, stages, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Imaging Test
  • Screening Test
  • Visual Examination
  • Cervical Biopsies
  • Other Procedures

On the basis of product type, the North America cervical cancer diagnostic market is segmented into imaging test, screening test, visual examination, cervical biopsies, and other procedures.

Age Group

  • Below 21
  • 21-29
  • 30-65
  • 65 and Above

On the basis of age group, the North America cervical cancer diagnostic market is segmented into below 21, 21-29, 30-65, and 65 and above.

Stages

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

On the basis of stage, the North America cervical cancer diagnostic market is segmented into stage I, stage II, stage III, and stage IV.

End Users

  • Cancer And Radiation Therapy Centers
  • Hospitals
  • Specialty Clinics
  • Cancer Research Organization
  • Diagnostic Laboratories
  • Community Health Centers

On the basis of end users, the North America cervical cancer diagnostic market is segmented into hospitals, diagnostic laboratories, specialty clinics, community health centers, cancer research organization, and cancer and radiation therapy centers.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Online Sales

Marché du diagnostic du cancer du col de l'utérus

On the basis of distribution channel, the North America cervical cancer diagnostic market is segmented into direct tender, retail sales, and online sales.

Cervical Cancer Diagnostic Market Regional Analysis/Insights 

The North America cervical cancer diagnostic market is analysed, and market size insights and trends are provided by country, product type, age group, stages, end users, and distribution channel as referenced above.

Some countries covered In the North America cervical cancer diagnostic market are the U.S., Canada, and Mexico.

The U.S. is expected to dominate the North America cervical cancer diagnostic market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising awareness of the early diagnosis of cervical cancer.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North American brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

North America Competitive Landscape and Cervical Cancer Diagnostic Market Share Analysis

The North America cervical cancer diagnostic market competitive landscape provides details of the competitors. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies focusing on the North America cervical cancer diagnostic market.

Some of the major players operating in the North America cervical cancer diagnostic market are Siemens Healthcare GmbH, BD, F. Hoffmann-La Roche Ltd, Abbott, Hologic, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., QIAGEN, The Cooper Companies Inc., Seegene Inc., Sysmex Corporation, MobileODT, Zilico, Jiangsu Mole Bioscience Co. Ltd., Guided Therapeutics, Inc., GenomeMe Lab Inc., Arbor Vita Corporation, and LCM GENECT Srl among others.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES MODEL

4.3 INDUSTRY INSIGHTS:

4.3.1 CERVICAL CANCER DIAGNOSIS

4.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE AND INCIDENCE OF CERVICAL CANCER

6.1.2 RISING AWARENESS OF EARLY DIAGNOSIS OF CERVICAL CANCER

6.1.3 HIGH PREVALENCE OF HPV-INFECTED PATIENTS AND RISING INCIDENCE OF TEENAGE SEXUAL ENCOUNTERS

6.2 RESTRAINTS

6.2.1 DEVELOPMENT IN THE FIELD OF HPV VACCINE

6.2.2 SIDE EFFECTS OF TREATMENT DRUGS

6.3 OPPORTUNITIES

6.3.1 RISING HEALTHCARE EXPENDITURE

6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT RULES AND REGULATIONS

6.4.2 FALSE RESULTS IN SCREENING TESTS AND UNAVAILABILITY OF IMPROVED HEALTHCARE INFRASTRUCTURE

7 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 SCREENING TEST

7.2.1 HPV TEST

7.2.1.1 ASSAYS

7.2.1.2 KITS/REAGENTS

7.2.2 PAP TEST

7.2.2.1 ASSAYS

7.2.2.2 KITS/REAGENTS

7.2.3 BLOOD TEST

7.3 IMAGING TEST

7.3.1 PET CT-SCAN

7.3.2 MAGNETIC RESONANCE IMAGING (MRI)

7.3.3 ULTRASOUND

7.3.4 X-RAY

7.3.5 OTHERS

7.4 CERVICAL BIOPSIES

7.4.1 LIQUID BIOPSY

7.4.2 ENDOCERVICAL CURETTAGE

7.4.3 COLPOSCOPIC BIOPSY

7.5 VISUAL EXAMINATION

7.5.1 CYSTOSCOPY

7.5.2 SIGMOIDOSCOPY

7.6 OTHER PROCEDURES

8 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP

8.1 OVERVIEW

8.2 30-65

8.3 65 AND ABOVE

8.4 21-29

8.5 BELOW 21

9 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY STAGES

9.1 OVERVIEW

9.2 STAGE I

9.3 STAGE II

9.4 STAGE III

9.5 STAGE IV

10 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY END USER

10.1 OVERVIEW

10.2 CANCER AND RADIATION THERAPY CENTERS

10.3 HOSPITALS

10.4 SPECIALTY CLINICS

10.5 CANCER RESEARCH ORGANIZATION

10.6 DIAGNOSTIC LABORATORIES

10.7 COMMUNITY HEALTH CENTERS

11 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.4 ONLINE SALES

12 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION

12.1 NORTH AMERICA

12.1.1 U.S.

12.1.2 CANADA

12.1.3 MEXICO

13 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 SIEMENS HEALTHCARE GMBH

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENT

15.2 BD

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 F. HOFFMANN- LA ROCHE LTD

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.4 ABBOTT

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENTS

15.5 HOLOGIC, INC.

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENTS

15.6 ARBOR VITA CORPORATION

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENTS

15.7 BIO-RAD LABORATORIES, INC.

15.7.1 COMPANY SNAPSHOT

15.7.2 REVENUE ANALYSIS

15.7.3 PRODUCT PORTFOLIO

15.7.4 RECENT DEVELOPMENT

15.8 GENOMEME LAB INC.

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 GUIDED THERAPEUTICS, INC

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENT

15.1 JIANGSU MOLE BIOSCIENCE CO., LTD.

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENTS

15.11 LCM GENECT SRL

15.11.1 COMPANY SNAPSHOT

15.11.2 PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 MOBILEODT

15.12.1 COMPANY SNAPSHOT

15.12.2 PRODUCT PORTFOLIO

15.12.3 RECENT DEVELOPMENT

15.13 QIAGEN

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 QUEST DIAGNOSTICS INCORPORATED

15.14.1 COMPANY SNAPSHOT

15.14.2 REVENUE ANALYSIS

15.14.3 PRODUCT PORTFOLIO

15.14.4 RECENT DEVELOPMENTS

15.15 SEEGENE INC.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENTS

15.16 SYSMEX CORPORATION

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 THE COOPER COMPANIES INC

15.17.1 COMPANY SNAPSHOT

15.17.2 REVENUE ANALYSIS

15.17.3 PRODUCT PORTFOLIO

15.17.4 RECENT DEVELOPMENT

15.18 ZILICO

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

Liste des tableaux

TABLE 1 CERVICAL CANCER CAN BE DIAGNOSED BY VARIOUS TESTS AND BIOPSIES, AS LISTED BELOW:

TABLE 2 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA SCREENING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA SCREENING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA HPV TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA PAP TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA IMAGING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA IMAGING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA CERVICAL BIOPSIES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA CERVICAL BIOPSIES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA VISUAL EXAMINATION IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA VISUAL EXAMINATION IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA OTHER PROCEDURES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA 30-65 IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA 65 AND ABOVE IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA 21-29 IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA BELOW 21 IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA STAGE I IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA STAGE II IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA STAGE III IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA STAGE IV IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA CANCER AND RADIATION THERAPY CENTERS IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA HOSPITALS IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA SPECIALTY CLINICS IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA CANCER RESEARCH ORGANIZATION IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA DIAGNOSTIC LABORATORIES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA COMMUNITY HEALTH CENTERS IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA DIRECT TENDER IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA RETAIL SALES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA ONLINE SALES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA SCREENING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA HPV TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA PAP TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA IMAGING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA CERVICAL BIOPSIES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA VISUAL EXAMINATION IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 47 U.S. CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 U.S. SCREENING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 49 U.S. HPV TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 50 U.S. PAP TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 U.S. IMAGING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 52 U.S. CERVICAL BIOPSIES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 53 U.S. VISUAL EXAMINATION IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 U.S. CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 55 U.S. CERVICAL CANCER DIAGNOSTIC MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 56 U.S. CERVICAL CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 57 U.S. CERVICAL CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 58 CANADA CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 59 CANADA SCREENING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 60 CANADA HPV TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 61 CANADA PAP TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 CANADA IMAGING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 63 CANADA CERVICAL BIOPSIES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 64 CANADA VISUAL EXAMINATION IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 65 CANADA CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 66 CANADA CERVICAL CANCER DIAGNOSTIC MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 67 CANADA CERVICAL CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 CANADA CERVICAL CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 69 MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 70 MEXICO SCREENING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 MEXICO HPV TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 MEXICO PAP TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 MEXICO IMAGING TEST IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 MEXICO CERVICAL BIOPSIES IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 75 MEXICO VISUAL EXAMINATION IN CERVICAL CANCER DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)

TABLE 77 MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, BY STAGES, 2021-2030 (USD MILLION)

TABLE 78 MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 79 MEXICO CERVICAL CANCER DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Liste des figures

FIGURE 1 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE AND INCIDENCE OF CERVICAL CANCER ARE EXPECTED TO DRIVE THE NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET IN THE FORECAST PERIOD

FIGURE 12 SCREENING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET

FIGURE 14 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY PRODUCT TYPE, 2022

FIGURE 15 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY AGE GROUP 2022

FIGURE 19 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY AGE GROUP, 2023-2030 (USD MILLION)

FIGURE 20 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY AGE GROUP, CAGR (2023-2030)

FIGURE 21 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY AGE GROUP, LIFELINE CURVE

FIGURE 22 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY STAGES, 2022

FIGURE 23 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY STAGES, 2023-2030 (USD MILLION)

FIGURE 24 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 25 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY STAGES, LIFELINE CURVE

FIGURE 26 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY END USER, 2022

FIGURE 27 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 28 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)

FIGURE 29 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET : BY END USER, LIFELINE CURVE

FIGURE 30 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 31 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 32 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 33 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)

FIGURE 35 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)

FIGURE 36 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)

FIGURE 37 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)

FIGURE 38 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: PRODUCT TYPE (2023-2030)

FIGURE 39 NORTH AMERICA CERVICAL CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The North America Cervical Cancer Diagnostic Market is projected to grow at a CAGR of 7.0% during the forecast period by 2030.
The future market value of the North America Cervical Cancer Diagnostic Market is expected to reach USD 5,516.97 million by 2030.
The major players in the North America Cervical Cancer Diagnostic Market are Siemens Healthcare GmbH, BD, F. Hoffmann-La Roche Ltd, Abbott, Hologic, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., QIAGEN, The Cooper Companies Inc., Seegene Inc., etc.
The countries covered in the North America Cervical Cancer Diagnostic Market are U.S., Canada, Mexico.